An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 03 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
- 21 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.